Anti-FCER2 therapeutic antibody (Pre-made Lumiliximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Lumiliximab is an IgG1k monoclonal antibody that targets CD23. It acts as an immunomodulator and was awarded orphan drug status and fast track designation by the FDA.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-327-1mg	1mg	3090
GMP-Bios-ab-327-10mg	10mg	21890
GMP-Bios-ab-327-100mg	100mg	148000
GMP-Bios-ab-327-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-FCER2 therapeutic antibody (Pre-made Lumiliximab biosimilar,Whole mAb)
INN Name	Lumiliximab
Target	FCER2
Format	Whole mAb
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	3fzu:HL:CD
95-98% SI Structure	None
Year Proposed	2004
Year Recommended	2004
Companies	Biogen Idec
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Allergic asthma;Allergic rhinitis;Chronic lymphocytic leukaemia
Development Tech	na